MacroGenics Inc. (MGNX), which has a diverse portfolio of oncology product candidates, is poised for multiple pipeline advancements this year.
The lead drug candidate is Vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a protein widely expressed by several different tumor types.
Vobra duo is being evaluated in a phase II trial in participants with metastatic castration resistant prostate cancer, dubbed TAMARACK. The study is fully enrolled with 177 patients, with initial clinical data anticipated in the second quarter of this year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.